Syndax Announces Participation at Two Upcoming Investor Conferences

Rhea-AI Summary

Syndax Pharmaceuticals, a clinical stage biopharmaceutical firm, will participate in two virtual investor conferences. The first event is a panel at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 11:40 a.m. ET. The second event is a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021, at 3:35 p.m. ET. Interested parties can access a live webcast of the Barclays presentation through the Company's website, where a replay will also be available. Syndax is developing innovative cancer therapies, including SNDX-5613, axatilimab, and entinostat.

News Market Reaction – SNDX

+10.27%

+10.27% Session move

In the trading session that priced this news, SNDX gained 10.27%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Feb. 24, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming virtual investor conferences:

• A panel at the Cowen 41st Annual Health Care Conference at 11:40 a.m. ET on Wednesday, March 3, 2021.
  
  
• A fireside chat at the Barclays Global Healthcare Conference at 3:35 p.m. ET on Tuesday, March 9, 2021.

A live webcast of the Barclays presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com 
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

 

View original content:http://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-301234357.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

What is Syndax Pharmaceuticals' participation in the Cowen 41st Annual Health Care Conference?

Syndax Pharmaceuticals will participate in a panel at the Cowen 41st Annual Health Care Conference on March 3, 2021, at 11:40 a.m. ET.

When is Syndax Pharmaceuticals' fireside chat at the Barclays Global Healthcare Conference?

The fireside chat will take place on March 9, 2021, at 3:35 p.m. ET.

How can I access the live webcast of Syndax's presentation at the Barclays Global Healthcare Conference?

The live webcast can be accessed from the Investor section of Syndax's website.

What therapies are being developed by Syndax Pharmaceuticals?

Syndax is developing SNDX-5613, axatilimab, and entinostat as part of its innovative cancer therapy pipeline.

What is the ticker symbol for Syndax Pharmaceuticals on Nasdaq?

The ticker symbol for Syndax Pharmaceuticals is SNDX.